{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:40Z","timestamp":1793211100168,"version":"4.5.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,2,15]]},"DOI":"10.2169\/internalmedicine.2553-18","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T22:04:57Z","timestamp":1581717897000},"page":"485-490","source":"Crossref","is-referenced-by-count":9,"title":["Symptomatic Characteristics of Parkinson's Disease Induced by Neuroleptic Drugs, Based on a Functional Neuroimaging Diagnosis"],"prefix":"10.2169","volume":"59","author":[{"given":"Kei","family":"Tachibana","sequence":"first","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Ii","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tomimoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 85: 322-326, 2009."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lopez-Sendon J, Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf 12: 487-496, 2013.","DOI":"10.1517\/14740338.2013.787065"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hassin-Baer S, Sirota P, Korczyn AD, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm (Vienna) 108: 1299-1308, 2001.","DOI":"10.1007\/s007020100006"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sethi KD, Zamrini EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry Clin Neurosci 2: 64-66, 1990.","DOI":"10.1176\/jnp.2.1.64"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP\/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 21: 510-514, 2006.","DOI":"10.1002\/mds.20748"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ba F, Martin WR. Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord 21: 87-94, 2015.","DOI":"10.1016\/j.parkreldis.2014.11.007"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yoshii F, Ryo M, Baba Y, Koide T, Hashimoto J. Combined use of dopamine transporter imaging (DAT-SPECT) and (123) I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease. J Neurol Sci 375: 80-85, 2017.","DOI":"10.1016\/j.jns.2017.01.042"},{"key":"8","unstructured":"8. Brigo F, Erro R, Marangi A, Bhatia K, Tinazzi M. Differentiating drug-induced parkinsonism from Parkinson's disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 20: 808-814, 2014."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson's disease. Mov Disord 30: 1600-1611, 2015.","DOI":"10.1002\/mds.26431"},{"key":"10","unstructured":"10. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59: 591-596, 2006."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Saito S, Ayabe-Kanamura S, Takashima Y, et al. Development of a smell identification test using a novel stick-type odor presentation kit. Chem Senses 31: 379-391, 2006.","DOI":"10.1093\/chemse\/bjj042"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kahraman D, Eggers C, Schicha H, Timmermann L, Schmidt M. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. J Neurol 259: 251-260, 2012.","DOI":"10.1007\/s00415-011-6163-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dickson JC, Tossici-Bolt L, Sera T, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging 37: 23, 2009.","DOI":"10.1007\/s00259-009-1212-z"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y, Ogawa T. Correlation between neuromelanin-sensitive MR imaging and (123) I-FP-CIT SPECT in patients with parkinsonism. Neuroradiology 58: 351-356, 2016.","DOI":"10.1007\/s00234-016-1644-7"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuda H, Murata M, Mukai Y, et al. Japanese multicenter database of healthy controls for [(123) I] FP-CIT SPECT. Eur J Nucl Med Mol Imaging 45: 1405-1416, 2018.","DOI":"10.1007\/s00259-018-3976-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H.  (123) I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67: 189-194, 1999.","DOI":"10.1136\/jnnp.67.2.189"},{"key":"17","unstructured":"17. Nakajima K, Okuda K, Matsuo S, et al. Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging 39: 113-119, 2012."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nakajima K, Okuda K, Yoshimura M, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 21: 970-978, 2014.","DOI":"10.1007\/s12350-014-9916-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hirose G. Drug induced parkinsonism. J Neurol 253: iii22-iii24, 2006.","DOI":"10.1007\/s00415-006-3004-8"},{"key":"20","unstructured":"20. Pieters LE, Bakker PR, van Harten PN. Asymmetric drug-induced parkinsonism and psychopathology: a prospective naturalistic study in long-stay psychiatric patients. Front Psychiatry 9: 18, 2018."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 56: 33-39, 1999.","DOI":"10.1001\/archneur.56.1.33"},{"key":"22","unstructured":"22. Shuaib UA, Rajput AH, Robinson CA, Rajput A. Neuroleptic-induced Parkinsonism: clinicopathological study. Mov Disord 31: 360-365, 2016."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Erro R, Bhatia KP, Tinazzi M. Parkinsonism following neuroleptic exposure: a double-hit hypothesis? Mov Disord 30: 780-785, 2015.","DOI":"10.1002\/mds.26209"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Foubert-Samier A, Helmer C, Perez F, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 79: 1615-1621, 2012.","DOI":"10.1212\/WNL.0b013e31826e25ce"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76: 249-251, 2005.","DOI":"10.1136\/jnnp.2004.037028"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Doty RL. Olfaction in Parkinson's disease. Parkinsonism Relat Disord 13 (Suppl 3): S225-S228, 2007.","DOI":"10.1016\/S1353-8020(08)70006-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tinazzi M, Ottaviani S, Isaias IU, et al. [123I] FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 23: 1825-1829, 2008.","DOI":"10.1002\/mds.22098"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Boeve BF, Silber MH, Saper CB, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130: 2770-2788, 2007.","DOI":"10.1093\/brain\/awm056"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 61: 164-170, 2009.","DOI":"10.1159\/000189269"},{"key":"30","unstructured":"30. Iijima M, Kobayakawa T, Saito S, et al. Smell identification in Japanese Parkinson's disease patients: using the odor stick identification test for Japanese subjects. Intern Med 47: 1887-1892, 2008."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_2553-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T03:39:20Z","timestamp":1581737960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_2553-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2553-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]}}}